OBIO
HEALTHCAREOrchestra BioMed Holdings Inc.
AI Insight
What's Moving OBIO Today?
No stock-specific AI insight has been generated for OBIO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.20$5.42
$4.09
Fundamentals
Market Cap$244M
P/E Ratio—
EPS$-0.95
Dividend Yield—
Dividend / Share—
ROE-161.1%
Profit Margin-167.0%
Debt / Equity—
Trading
Volume47K
Avg Volume (10D)—
Shares Outstanding59.9M
OBIO News
23 articles- Sidoti Events, LLC's June Small-Cap Virtual ConferenceYahoo Finance·Jun 16, 2026
- OBIO: Upcoming BackBeat and Virtue trial milestones signal strong growth and partnership-driven valueTradingView·Jun 4, 2026
- New hires at Orchestra BioMed receive options on 85,500 sharesStock Titan·Jun 3, 2026
- Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jun 2, 2026
- Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired StockYahoo Finance·May 21, 2026
- Orchestra BioMed to Participate in the Jefferies Global Healthcare ConferenceYahoo Finance·May 19, 2026
- Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 12, 2026
- Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business UpdatesYahoo Finance·May 12, 2026
- Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027Yahoo Finance·May 12, 2026
- Ligand (LGND) Completes $15M Investment in Orchestra BioMedGuruFocus·May 8, 2026
- Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 6, 2026
- Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing AgreementYahoo Finance·May 6, 2026
- Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing AgreementYahoo Finance·May 6, 2026
- FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM TherapyYahoo Finance·Apr 30, 2026
- NovoCure (NVCR) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·Apr 30, 2026
- Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026Yahoo Finance·Apr 23, 2026
- Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue EstimatesYahoo Finance·Mar 12, 2026
- Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business UpdateYahoo Finance·Mar 12, 2026
- Codexis (CDXS) Beats Q4 Earnings and Revenue EstimatesYahoo Finance·Mar 11, 2026
- Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRTYahoo Finance·Mar 3, 2026
- Orchestra BioMed to Participate in Upcoming Institutional Investor ConferencesYahoo Finance·Feb 19, 2026
- Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) largest shareholders are retail investors with 41% ownership, institutions own 17%Yahoo Finance·Jan 22, 2026
All 23 articles loaded
Price Data
Open$4.05
Previous Close$4.04
Day High$4.12
Day Low$4.02
52 Week High$5.42
52 Week Low$2.20
52-Week Range
$2.20$5.42
$4.09
Fundamentals
Market Cap$244M
P/E Ratio—
EPS$-0.95
Dividend Yield—
Dividend / Share—
ROE-161.1%
Profit Margin-167.0%
Debt / Equity—
Trading
Volume47K
Avg Volume (10D)—
Shares Outstanding59.9M
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. The company is headquartered in New Hope, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—